Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 7, 2012, Pages 958-965

  Ahmed, Hanaa H ^a   Metwally, F M ^a   Mahdy, E S M ^b   Shosha, W G ^b   Ramadan, S S ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Helwan University   (Egypt)

Author keywords

Bcl 2; Breast cancer; Diagnosis; HGF; NO; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; NITRIC OXIDE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; SCATTER FACTOR; TUMOR MARKER;

ADULT; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC VALUE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; POSTMENOPAUSE; REVIEW; TUMOR BIOPSY; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EGYPT; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864231110     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. PARKIN DM, BRAY F, FERLAY J, PISANI P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. BENSON JR, JATOI I, KEISCH M, ESTEVA FJ, MAKRIS A, JORDAN VC. Early breast cancer. Lancet 2009; 373: 1463-1479.
3. HAYES DF, BAST RC, DESCH CE, FRITSCHE H, JR KEMENY NE, JESSUP JM, LOCKER GY, MACDONALD JS, MENNEL RG, NORTON L, RAVDIN P, TAUBE S, WINN RJ. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
4. BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VANDE WOUDE GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
5. YANG Y, SPITZER E, MEYER D, SACHS M, NIEMANN C, HARTMANN G, WEIDNER KM, BIRCHMEIER C, BIRCHMEIER W. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol 1995; 131: 215-226.
6. ANDERMARCHER E, SURANI MA, GHERARDI E. Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev Genet 1996; 18: 254-266.
7. WEIDNER KM, SACHS M, BIRCHMEIER W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/ hepatocyte growth factor in epithelial cells. J Cell Biol 1993; 121: 145-154.
8. CORSO S, COMOGLIO PM, GIORDANO S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005; 11: 284-292.
9. YAMASHITA J, OGAWA M, YAMASHITA S, NOMURA K, KURAMOTO M, SAISHOJI T, SHIN S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54: 1630-1633.
10. SHEEN-CHEN SM, LIU YW, ENG HL, CHOU FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 715-717.
11. BOROS P, MILLER CM. Hepatocyte growth factor: A multifunctional cytokine. Lancet 1995; 345: 293-295.
12. NISHINO M, IIMURO Y, UEKI T, HIRANO T, FUJIMOTO J. Hepatocyte growth factor improves survival after partial hepatectomy in cirrhotic rats suppressing apoptosis of hepatocytes. Surgery 2008; 144: 374-384.
13. KONNO R, TAKANO T, SATO SH, YAJIMA A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576-3580.
14. REED JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
15. WHITE E. Life, death and the pursuit of apoptosis. A review. Genes Dev 1996; 10: 1-15.
16. CALLAGY GM, WEBBER MJ, PHAROAH PDP, CALDAS C. Meta-Analysis confirms Bcl-2 is an independent prognostic marker in breast cancer. BMC Cancer 2008; 8: 153.
17. MCDONNELL TJ, KORSMEYER SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18). Nature 1991; 349: 254-256.
18. PIETENPOL JA, PAPADOPOULOS N, MARKOWITZ S, WILLSON JK, KINZLER KW, VOGELSTEIN B. Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 1994; 54: 3714-3717.
19. VAN SLOOTEN HJ, CLAHSEN PC, VAN DIERENDONCK JH, DUVAL C, PALLUD C, MANDARD AM, DELOBELLEDEROIDE A, VAN DE VELDE CJ, VAN DE VIJVER MJ. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to onecourse of perioperative chemotherapy. Br J Cancer 1996; 74: 78-85.
20. LEE KH, IM SA, OH BY, LEE SH, CHIE EK, HAN W, KIM DW, KIM TY, PARK IA, NOH DY, HEO DS, HA SW, BANG YJ. Prognostic significance of Bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007; 7: 63.
21. NADLER Y, CAMP RL, GILTNANE JM, MOEDER C, RIMM DL, KLUGER HM, KLUGER Y. Expression patterns and prognostic value of Bag- 1 and Bcl-2 in breast cancer. Breast Cancer Res 2008; 10: 35.
22. LINJAWI A, KONTOGIANNEA M, HALWANI F, EDWARDES M, METERISSIAN S. Prognostic significance of p53, Bcl- 2, and Bax expression in early breast cancer. J Am Coll Surg 2004; 198: 83-90.
23. BILALOVIC N, VRANIC S, HASANAGIC S, BASIC H, TATAREVIC A, BESLIJA S. The Bcl-2 protein: A prognostic indicator strongly related to ER and PR in breast cancer. Bosn J Basic Med Sci 2004; 4: 5-12.
24. IGNARRO L. Nitric oxide biology and pathobiology. New York: Academic Press; 2000.
25. XU W, LIU LZ, LOIZIDOU M, AHMED M, CHARLES IG. The role of nitric oxide in cancer. Cell Res 2002; 12: 311-320.
26. RAJNAKOVA A, MOOCHHALA S, GOH MYP, NGOI SS. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stage of human gastric cancer. Cancer Lett 2001; 172: 177-185.
27. EROGLU A, DEMIRCI S, AYILIZ, KOCAOGLU H, AKBULUT H, AKGÜL H, ELHAN HA. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 1999; 80: 1630-1634.
28. CIANCHI F, CORTESINI C, FANTAPPIE O, MESSERINI L, SARDI I, LASAGNA N, PERNA F, FABBRONI V, DI FELICE A, PERIGLI G, MAZZANTI R, MASINI E. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004; 10: 2694-2704.
29. MOLLACE V, MUSCOLI C, MASINI E, CUZZOCREA S, SALVEMINI D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005; 57: 217-252.
30. THUN MJ, HENLEY SJ, PATRONO C. Nonsteroidal antiinflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-266.
31. BARBARESCHI M, CAFFO O, VERONESE S, LEEK RD, FINA P, FOX S, BONZANINI M, GIRLANDO S, MORELLI L, ECCHER C, PEZZELLA F, DOGLIONI C, PALMA PD, HARRIS A. Bcl-2 and p53 expression in node negative breast carcinoma a study with long term follow up. Human Pathol 1996; 27: 1149-1155.
32. PLUM L, LIN HV, DUTIA R, TANAKA J, AIZAWA KS. The obesity susceptibility gene carboxypeptidase E links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake. Nature Med 2009; 15: 1195-1201.
33. MONTGOMERY HAC, DYMOCK JF. Analyst 1961; 86: 414.
34. BROOKS M. Breast cancer screening and biomarkers. Methods Mol Biol 2009; 472: 307-321.
35. MATSUMOTO K, NAKAMURA T, SAKAI K, NAKAMURA T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008;8: 3360-3370.
36. TAJIMA H, MATSUMOTO K, NAKAMURA T. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett 1991; 291: 229-232.
37. SESLAR SP, NAKAMURA T, STEPHEN WB. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res 1993; 53: 1233-1238.
38. MATSUMOTO K, TAJIMA H, NAKAMURA T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun 1991;176: 45-51.
39. MAEJIMA Y, UEBA H, KUROKI M, YASU T, HASHIMOTO S, NABATA A, KOBAYASHI N, IKEDA N, SAITO M, KAWAKAMI M. Src family kinases and nitric oxide production are required for hepatocyte growth factor stimulated endothelial cell growth. Atherosclerosis 2003; 167: 89-95.
40. BELL LN, CAI L, JOHNSTONE BH, TRAKTUEV DO, MARCH KL, CONSIDINE RV. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am J Physiol Endocrinol Metab 2008; 294: 336-344.
41. TOMITA N, MORISHITA R, TANIYAMA Y, KOIKE H, AOKI M, SHIMIZU H, MATSUMOTO K, NAKAMURA T, KANEDA Y, OGIHARA T. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-1417.
42. ROSEN EM, LAMSZUS K, LATERRA J, POLVERINI PJ, RUBIN JS. Goldberg ID HGF/SF in angiogenesis. Ciba Found Symp 1997; 212: 215-226.
43. SHEEN-CHEN SM, LIU YW, ENG HL, CHOU FF. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 715-717.
44. HOCKENBERY DM, ZUTTER M, HICKEY W, NAHM M, KORSMEYER SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci 1991; 88: 6961-6965.
45. CHAO DT, KORSMEYER SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
46. LUNA-MORÉ S, CASQUERO S, PEREZ-MELLADO A, RIUS F, WEILL B, GORNEMANN I. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol Res Pract 2000; 196: 35-39.
47. WANG S, YANG D, LIPPMAN ME. Targeting Bcl-2 and Bcl-XL with non peptidic small-molecule antagonists. Semin Oncol 2003; 30: 132-142.
48. LEE KH, IM SA, OH DY, LEE SH, CHIE EK, HAN W, KIM DW, KIM TY, PARK IA, NOH DY, HEO DS, HA SW, BANG YJ. Prognostic significance of Bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007; 7: 63.
49. REHMAN S, CROW J, REVELL PA. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 2000; 6: 256-263.
50. SIERRA A, CASTELLSAGUE X, ESCOBEDO A, LLOVERAS B, GARCIA- RAMIREZ M, MORENO A, FABRA A. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer. Int J Cancer 2000; 89: 142-147.
51. FERNANDEZ Y, GU B, MARTINEZ A, TORREGROSA A, SIERRA A. Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state. Int J Cancer 2002;101: 317-326.
52. GASPARINI G, BARBARESCHI M, DOGLIONI C, PALMA PD, MAURI FA, BORACCHI P, BEVILACQUA P, CAFFO O, MORELLI L, VERDERIO P, PEZZELLA F, HARRIS AL. Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-198.
53. TSUTSUI S, YASUDA K, SUZUKI K, TAKEUCHI H, NISHIZAKI T, HIGASHI H, SF ERA. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer 2006; 6: 187.
54. KALLEL-BAYOUDH I, HASSEN HB, KHABIR A, BOUJELBENE N, DAOUD J, FRIKHA M, SALLEMI-BOUDAWARA T, AIFA S, REBAI A. Bcl-2 expression and triple negative profile in breast carcinoma. Med Oncol 2010 Oct 2. [Epub ahead of print]
55. DU M, SINGH N, HUSSEUIN A, ISAACSON PG, PAN L. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-Associated lymphoid tissue (MALT). J Pathol 1996; 178: 379-384.
56. MARTIN JHJ, ALALAMI O, VAN DEN BERG HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett 1999; 144: 65-74.
57. MACRITCHIE AN, JUN SS, CHEN Z, GERMAN Z, YUHANNA IS, SHERMAN TS. Estrogen up regulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997; 81: 355-362.
58. SYLVIE R, LAVENT A, GENEVIEVE J, SOPHIE K, PASCALE L, VALERIE S. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate and expression of progesterone receptors. Lab Invest 1999; 79: 1215-1225.
59. GUNEL N, COSKUN U, SANCAK B, HASDEMIR O, SARE M, BAYRAM O, CELENKOGLU G, OZKAN S. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003; 26: 416-421.
60. MARTIN JH, BEGUM S, ALALAMI O, HARRISON A, SCOTT KW. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 2000; 21: 90-97.
61. LANGREHR JM, LANGREHR JM, MURASE N, MARKUS PM, CAI X, NEUHAUS P, SCHRAUT W, SIMMONS RL, HOFFMAN RA. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679-683.